Pneumonia in Children

• Pathogen Entry and Mucosal Breach: Respiratory pathogens reach the lung parenchyma through three main routes: (1) aspiration of colonized nasopharyngeal secretions (most common in young children), (2) inhalation of aerosolized particles from infected individuals, or (3) hematogenous seeding from distant infection sites. The initial step involves bypassing or overwhelming upper airway defense mechanisms (mucociliary clearance, lysozyme, lactoferrin, IgA) and innate immune barriers (complement, resident macrophages). Young children have immature immune responses and reduced ability to generate robust local IgA responses, increasing susceptibility. Viral pathogens (particularly respiratory syncytial virus [RSV] and influenza) directly infect respiratory epithelial cells, causing ciliary dysfunction and disrupting the epithelial barrier, which secondarily facilitates bacterial superinfection. Bacterial pathogens such as Streptococcus pneumoniae produce proteases and toxins that damage epithelial integrity; pneumolysin, a cholesterol-dependent cytolysin, creates pores in epithelial and immune cells, impairing clearance and promoting dissemination.

• Innate Immune Activation and Inflammatory Cascade: Once pathogens breach epithelial defenses, resident alveolar macrophages and dendritic cells recognize pathogen-associated molecular patterns (PAMPs) through pattern recognition receptors (TLRs, NOD-like receptors, C-type lectin receptors). This triggers rapid transcription of pro-inflammatory cytokines—particularly TNF-α, IL-1β, IL-6, and IL-8—through NF-κB and MAPK signaling pathways. These cytokines upregulate adhesion molecules (ICAM-1, VCAM-1, selectins) on endothelial cells, recruiting neutrophils via chemokine gradients (especially CXCL8/IL-8 and CCL2/MCP-1). This massive neutrophil infiltration, while necessary for pathogen clearance, simultaneously causes collateral tissue damage through release of proteases (elastase, collagenase), reactive oxygen species (ROS), and neutrophil extracellular traps (NETs). In young children, this inflammatory response is often exaggerated relative to bacterial burden, explaining why clinical severity sometimes exceeds objective infectious burden. Additionally, complement activation (both classical and alternative pathways) generates C5a, a potent neutrophil chemoattractant, further amplifying inflammation.

• Alveolar-Capillary Membrane Dysfunction and Gas Exchange Impairment: Pathologic inflammation damages the delicate alveolar-capillary interface, comprising the respiratory epithelium, basement membrane, and capillary endothelium. Endothelial injury increases capillary permeability, leading to alveolar edema—accumulation of protein-rich fluid in the alveolar space that impairs oxygen diffusion and creates a mechanical barrier between air and blood. Simultaneously, epithelial cell injury reduces surfactant production and function; surfactant dysfunction increases alveolar surface tension, promoting alveolar collapse (atelectasis) and ventilation-perfusion (V/Q) mismatch. The combination of edema, atelectasis, and inflammation creates areas of intrapulmonary shunting where perfused but unventilated alveoli result in deoxygenated blood returning to systemic circulation, causing hypoxemia refractory to supplemental oxygen. In infants and young children with smaller airways and less collateral ventilation (pores of Kohn, canals of Lambert), airway obstruction by mucus and inflammatory exudate more readily causes obstruction-induced atelectasis and air trapping, driving the characteristic tachypnea and increased work of breathing. The mechanical work required to overcome increased elastic recoil (from edema) and airway resistance (from obstruction and mucus) manifests clinically as retractions, nasal flaring, and grunting.

• Metabolic Consequences and Systemic Effects: As pneumonia progresses, systemic inflammation triggers fever through IL-1β and TNF-α effects on the hypothalamic set point, increasing metabolic rate. Hypoxemia stimulates the respiratory centers, increasing minute ventilation and minute work of breathing; this hyperventilation partially compensates for V/Q mismatch through increased overall alveolar ventilation, but at the cost of increased metabolic demand. In severe cases, inadequate oxygenation despite compensation leads to anaerobic metabolism, lactic acidosis, and cellular dysfunction. Inflammatory cytokines impair cardiac contractility and vascular tone regulation, potentially precipitating septic shock with hypotension, end-organ hypoperfusion, and multi-system organ dysfunction. Bacterial pathogens may produce toxins (e.g., pneumolysin from pneumococci) that directly impair myocardial function and increase capillary permeability. In viral pneumonias, particularly severe RSV infections, bronchiolitis—inflammation of small bronchioles—creates dynamic airway obstruction from mucus plugging and edema, explaining the characteristic wheezing and air trapping that may paradoxically appear as hyperinflation on chest X-ray.

• Age-Related Variation in Pathophysiology: The immature immune system in infants (particularly <6 months) shows reduced capacity for opsonophagocytosis of encapsulated bacteria due to lower baseline IgG levels and impaired specific antibody responses; this explains the broader spectrum of bacterial pathogens causing disease in this age group, including Group B Streptococcus (GBS) and gram-negative enterics that are unusual in older children. Toddlers (6 months to 5 years) have developing but still-immature adaptive immunity, explaining the peak incidence of viral bronchiolitis and the prevalence of respiratory viral pathogens in this age group. By school age (≥5 years), immune maturation allows more effective bacterial clearance, though atypical organisms like Mycoplasma pneumoniae become relatively more common.

Viral Pathogens (Most Common Overall, Especially in <5 Years)

• Respiratory Syncytial Virus (RSV): Accounts for 70–80% of bronchiolitis cases in infants <12 months and 30–40% of lower respiratory tract infections in children <5 years. RSV causes particularly severe disease in infants born prematurely, those with chronic lung disease (bronchopulmonary dysplasia), congenital heart disease, and immunocompromised children. The pathophysiology involves direct epithelial infection causing bronchiolar obstruction and air trapping.
• Influenza viruses (A and B): More common in older children and school-age populations, particularly during winter months. Risk is elevated in children with chronic medical conditions (asthma, cystic fibrosis, cardiac disease, neuromuscular disorders), diabetes, and immunosuppression.
• Parainfluenza viruses (types 1, 2, 3): Common in infants and young children; type 1 shows a biennial autumn peak.
• Human metapneumovirus, rhinovirus, and enterovirus: Increasingly recognized as causes of significant lower respiratory infection in children of all ages.
• Adenovirus: Associated with particularly severe pneumonia in previously healthy children; certain serotypes (3, 7, 21) are particularly virulent.
• Coronavirus, including SARS-CoV-2: Increasingly documented as a cause of pediatric pneumonia; typically milder in children than in adults, but severe cases occur.

Bacterial Pathogens (Age-Dependent Distribution)

• Neonates (0–28 days): Group B Streptococcus (GBS), Escherichia coli (particularly K1 strain), Listeria monocytogenes, and other gram-negative enteric organisms. GBS typically presents within first 48–72 hours of life; acquisition occurs during maternal colonization in the genital tract, and horizontal transmission from environment is minimal. E. coli K1 infection is associated with maternal genitourinary colonization. Risk is increased in premature rupture of membranes (PROM), chorioamnionitis, and prematurity.
• Infants (1–3 months): GBS, Gram-negative enteric organisms, and beginning emergence of Haemophilus influenzae type b (Hib)—though Hib is now rare in vaccinated populations. Chlamydia trachomatis causes a distinctive "afebrile pneumonia" syndrome around 4–12 weeks of age (see Clinical Presentation).
• Older Infants and Young Children (4 months–5 years): Streptococcus pneumoniae (most common bacterial pathogen in this age group, still despite pneumococcal vaccines), Haemophilus influenzae type b (rare in vaccinated populations), Moraxella catarrhalis, and group A Streptococcus (less common). S. pneumoniae remains important because vaccine coverage is incomplete and non-vaccine serotypes (particularly serotypes 3 and 19A) continue to circulate.
• School-Age Children (≥5 years): Streptococcus pneumoniae (still most common bacterial cause), Mycoplasma pneumoniae (increasing prevalence), Chlamydia pneumoniae, and Haemophilus influenzae type b (rare in vaccinated populations). Mycoplasma becomes relatively more important in this age group and accounts for 5–15% of community-acquired pneumonia (CAP) cases; it has a predilection for causing atypical pneumonia with prominent constitutional symptoms and radiographic findings that appear more severe than clinical illness suggests.

Atypical Pathogens in Older Children

• Mycoplasma pneumoniae: Causes CAP particularly in children >5 years; associated with extrapulmonary manifestations (erythema multiforme, hemolytic anemia, encephalitis, myocarditis) due to immune-mediated mechanisms. Mycoplasma produces hydrogen peroxide and superoxide radicals, damaging epithelial cells.
• Chlamydia pneumoniae: Causes mild CAP in older children; more common in adults.
• Legionella pneumophila: Rare in children but important in epidemiologic contexts of water system contamination.

Risk Factors for Pneumonia

• Age <5 years: Peak incidence of viral pneumonia and bacterial CAP; immature immune system.
• Prematurity and low birth weight: Reduced lung development, lower antibody levels, increased Hib and other gram-negative infections.
• Chronic underlying disease: Asthma, cystic fibrosis, chronic lung disease (BPD), congenital heart disease (increased risk of pneumococcal and other bacterial infections).
• Immunocompromise: HIV/AIDS, malignancy with chemotherapy, post-transplant immunosuppression, primary immunodeficiencies (increases risk of unusual organisms including Pneumocystis jirovecii pneumonia [PCP], cytomegalovirus [CMV], fungal infections).
• Neuromuscular disorders: Cerebral palsy, muscular dystrophies—increased aspiration risk.
• Gastroesophageal reflux disease (GERD): Facilitates aspiration and recurrent pneumonia.
• Malnutrition and poverty: Associated with reduced immune function and environmental exposures.
• Passive smoke exposure: Impairs mucociliary clearance and increases airway inflammation.
• Day care or school attendance: Increased viral exposure and transmission of respiratory pathogens.
• Recent viral infection: Particularly influenza; increases risk of secondary bacterial superinfection (especially with Staphylococcus aureus, including methicillin-resistant S. aureus [MRSA], and Group A Streptococcus).
• Aspiration risk factors: Cleft palate, tracheoesophageal fistula, swallowing dysfunction—increase risk of aspiration pneumonia with anaerobic organisms and oral flora.

Cardinal Respiratory Symptoms

• Cough: Present in >80% of pneumonia cases; typically begins as dry, non-productive cough and may progress to productive cough with sputum or hemoptysis (though young children often swallow sputum and don't expectorate). Viral etiologies typically cause persistent, paroxysmal cough with prominent upper respiratory symptoms (rhinorrhea, pharyngitis), while bacterial CAP cough may be more focal. The cough results from airway irritation from inflammation, edema, and secretions.
• Tachypnea: One of the most sensitive early findings and is the hallmark sign driving the diagnosis of pneumonia in children; physiologic basis is hypoxemia and increased work of breathing from decreased lung compliance (due to edema and atelectasis). The WHO defines fast breathing as respiratory rate thresholds that vary by age: RR ≥50/min in children 2–11 months, RR ≥40/min in children 12–59 months, and RR ≥30/min in children ≥5 years. Tachypnea may persist for 1–2 weeks after appropriate antibiotic initiation due to ongoing inflammation.
• Dyspnea and increased work of breathing: Manifests as retractions (intercostal, subcostal, suprasternal), nasal flaring, and grunting (expiratory grunting represents "pursed-lip" breathing used to maintain positive end-expiratory pressure [PEEP] and prevent alveolar collapse). These findings indicate increased elastic recoil and work against decreased lung compliance. Grunting is particularly ominous and suggests severe pneumonia with impending respiratory failure.
• Wheezing and crackles on auscultation: Wheezing (polyphonic or monophonic) indicates airway obstruction and is particularly common in viral bronchiolitis (RSV, parainfluenza); it may be confused with asthma exacerbation but lacks the chronicity of asthma. Fine crackles (rales) on auscultation represent fluid in alveoli and small airways; they may be absent early in consolidation but become more prominent in resolving pneumonia as secretions mobilize. Dullness to percussion and bronchial breath sounds indicate consolidation and are more common in bacterial pneumonia.
• Dyspnea with minimal cough (Chlamydia trachomatis pneumonia in young infants): A distinctive presentation in infants 4–12 weeks of age born to mothers with untreated chlamydial infection; characterized by afebrile pneumonia, progressive tachypnea (RR 60–80/min), and absence of significant cough initially, with gradual onset over 1–3 weeks. Radiograph shows bilateral infiltrates. Associated with eosinophilia (absolute eosinophil count >400/μL) and elevated IgM.

Systemic Symptoms

• Fever: Present in 60–80% of bacterial pneumonia but less common in viral pneumonia (particularly RSV infection). Fever is mediated by IL-1β, TNF-

Initial evaluation

• Pulse oximetry: obtain in every child with suspected pneumonia. The IDSA/PIDS pediatric community-acquired pneumonia (CAP) guideline uses SpO2 <90% on room air as a threshold for hospitalization, because it signals shunt physiology from alveolar filling and atelectasis rather than simple V/Q mismatch.
• Clinical diagnosis first: in a well-appearing, fully immunized outpatient, IDSA/PIDS explicitly states that routine chest radiography is not required — tachypnea plus focal findings suffices to start therapy. Imaging does not reliably separate viral from bacterial disease.

Imaging (confirmatory)

• Chest radiograph, PA and lateral: indicated for hypoxemia, significant distress, failure of outpatient therapy, suspected complication, or any hospitalized child. Lobar/segmental consolidation with air bronchograms suggests typical bacterial disease (S. pneumoniae); diffuse perihilar/interstitial infiltrates with hyperinflation suggest viral disease; round pneumonia in a young child is classically pneumococcal.
• Repeat/lateral decubitus imaging or ultrasound when effusion is suspected; point-of-care lung ultrasound is increasingly used and avoids radiation.

Microbiology

• Blood cultures: not recommended for outpatients; obtain in moderate-to-severe hospitalized CAP and in any child failing therapy. Yield is low but a positive culture defines therapy.
• Viral PCR (nasopharyngeal): influenza and multiplex respiratory panels — a positive influenza or RSV test in a non-toxic child reduces unnecessary antibiotics.
• ***Mycoplasma pneumoniae* PCR**: for school-age children with atypical features; cold agglutinins are a classic but nonspecific clue.
• Sputum Gram stain/culture: only useful in older children who can expectorate.

Ancillary and pleural studies

• CBC, CRP, procalcitonin: IDSA/PIDS does not endorse these to distinguish viral from bacterial etiology in isolation; they track severity and response.
• Pleural fluid analysis when an effusion is drained: exudative fluid with low pH, low glucose, high LDH, or a positive Gram stain/culture defines a complicated parapneumonic effusion requiring drainage rather than antibiotics alone.

Immediate stabilization

• Oxygen and airway support: supplemental oxygen for SpO2 <90–92%; escalate to high-flow nasal cannula or noninvasive ventilation for grunting, severe retractions, or rising PaCO2. Isotonic IV fluids for dehydration, with attention to hyponatremia from SIADH.

First-line antimicrobial therapy (IDSA/PIDS pediatric CAP guideline)

• Aminopenicillin — high-dose amoxicillin, 90 mg/kg/day divided BID–TID: outpatient therapy of choice for presumed bacterial CAP in a fully immunized child, because high serum levels overcome the altered penicillin-binding proteins of intermediate-resistance pneumococcus.
• Ampicillin or penicillin G IV: preferred inpatient regimen for the fully immunized child in areas without high-level penicillin resistance.
• Third-generation cephalosporin — ceftriaxone: for incompletely immunized children, severe disease, or regions of high-level resistance.
• Macrolide — azithromycin: added when atypical pathogens (Mycoplasma, Chlamydia pneumoniae) are suspected in school-age children; used alone only when atypical disease is the sole consideration.
• Neuraminidase inhibitor — oseltamivir: start early for suspected or confirmed influenza; do not delay for test results in hospitalized or high-risk children.

Escalation

• Anti-MRSA agent — vancomycin or clindamycin: add for necrotizing pneumonia, empyema, pneumatoceles, or post-influenza staphylococcal disease. Vancomycin is dosed to a 24-hour AUC with an AUC/MIC target of 400–600 per the 2020 IDSA/ASHP consensus; the old 15–20 mcg/mL trough goal is retired.

Definitive/procedural management

• Drainage of complicated effusion/empyema: chest tube with intrapleural fibrinolytics or VATS decortication; both are accepted by IDSA/PIDS, with choice driven by local expertise.

What not to do

• No antibiotics for bronchiolitis or documented viral pneumonia — AAP bronchiolitis guideline also advises against routine bronchodilators, corticosteroids, and chest physiotherapy.
• Avoid fluoroquinolones as first line in children; reserve for resistant organisms or beta-lactam allergy.
• Do not withhold beta-lactams for a vague "penicillin allergy" — cephalosporin cross-reactivity is roughly 1–3%, driven by shared R1 side chains, not the beta-lactam ring.

Pulmonary complications

• Parapneumonic effusion and empyema: cytokine-driven capillary leak and pleural inflammation produce exudate that becomes loculated as fibrin deposits. Signaled by persistent fever beyond 48–72 hours of appropriate antibiotics, dullness to percussion, and a layering or loculated collection on decubitus film/ultrasound. Most common with S. pneumoniae, S. aureus, and group A Streptococcus.
• Necrotizing pneumonia and lung abscess: pneumolysin and staphylococcal toxins (including Panton-Valentine leukocidin) cause parenchymal liquefaction; look for cavitation on imaging and a protracted septic course.
• Pneumatocele: thin-walled air cysts from check-valve airway damage, classically S. aureus; usually resolves spontaneously but can rupture.
• Pneumothorax, especially tension pneumothorax: emergency — sudden desaturation, absent breath sounds, tracheal deviation, hypotension. Needle decompression precedes imaging.
• Respiratory failure/ARDS: emergency; rising PaCO2, apnea, or exhaustion in a previously tachypneic child means intubation, not more oxygen.

Systemic complications

• Bacteremia and septic shock: emergency; pneumococcal or staphylococcal seeding with meningitis, septic arthritis, or osteomyelitis.
• Hemolytic uremic syndrome: pneumococcal neuraminidase strips sialic acid and exposes the Thomsen-Friedenreich (T) antigen; suspect with anemia, thrombocytopenia, and rising creatinine.
• SIADH with hyponatremia: nonosmotic ADH release from lung inflammation; seizures if severe.
• ***Mycoplasma* extrapulmonary disease**: cold-agglutinin hemolytic anemia, *erythema multiforme*/mucositis, encephalitis — immune-mediated, not direct invasion.

Treatment-related complications

• **Antibiotic-associated diarrhea and C. difficile colitis**: highest with clindamycin and broad cephalosporins.
• Drug eruption: aminopenicillin plus concurrent EBV yields a florid morbilliform rash that is not true IgE allergy.
• Vancomycin nephrotoxicity and infusion reaction; macrolide QT prolongation, and infantile hypertrophic pyloric stenosis with macrolide exposure in young infants.

• Tachypnea is the most sensitive sign: a child with cough and a normal respiratory rate very likely does not have pneumonia. WHO age-based cut-offs drive the clinical diagnosis; a normal chest film does not exclude early disease.
• High-dose amoxicillin is the single best next step for presumed bacterial CAP in a fully immunized outpatient. The classic distractor is azithromycin monotherapy in a preschooler — atypicals are uncommon under age 5, and macrolide resistance in pneumococcus is substantial.
• Afebrile pneumonia of infancy: a 4–12-week-old with staccato cough, tachypnea, conjunctivitis history, bilateral infiltrates, and eosinophilia is Chlamydia trachomatis. Treat with a macrolide; remember the pyloric stenosis association in young infants.
• Walking pneumonia: school-age child, gradual onset, radiograph looks worse than the patient, positive cold agglutinins, sometimes bullous myringitis or erythema multiforme — Mycoplasma pneumoniae, treat with a macrolide.
• Post-influenza deterioration with pneumatoceles, empyema, or necrosis = Staphylococcus aureus; add an anti-MRSA agent (vancomycin or clindamycin). Do not simply broaden the cephalosporin.
• Round pneumonia on film in a young child is pneumococcal, not a mass — do not order a CT chest as the next step.
• Persistent fever after 48–72 hours of appropriate antibiotics means look for a parapneumonic effusion/empyema: ultrasound or decubitus film, then drainage — not reflexive antibiotic escalation.
• The one association examiners love: pneumococcal pneumonia → neuraminidase exposes the T antigen → hemolytic uremic syndrome. Distinguish it from Shiga toxin HUS, which follows bloody diarrhea.
• Common distractor: wheezing infant under 12 months with RSV — this is bronchiolitis, and per the AAP guideline management is supportive; antibiotics, steroids, and bronchodilators are all wrong answers.